Hong Kong
· Delayed Price · Currency is HKD Zai Lab Company Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions.
It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT.
The company was incorporated in 2013 and is headquartered in Shanghai, China.
| Country | Cayman Islands |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,175 |
| CEO | Ying Du |
Contact Details
Address: Jinchuang Plaza Shanghai, 201210 China | |
| Phone | 86 21 6163 2588 |
| Website | zailaboratory.com |
Stock Details
| Ticker Symbol | 9688 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | KYG9887T1168 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson and Chief Executive Officer |
| Joshua L. Smiley | President and Chief Operating Officer |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research and Development |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer |
| Dr. Peter Huang Ph.D. | Chief Scientific Officer |
| Christine Chiou | Senior Vice President and Head of Investor Relations |
| Frazor Titus Edmondson III, J.D. | Chief Legal Officer and Joint Corporate Secretary |
| Dr. Ning Xu M.D. | Executive Vice President and Head of Clinical Operations |
| Dr. Jonathan J. Wang MBA, Ph.D. | Chief Business Officer |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Research & Development |